MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2025)
MoonLake Immunotherapeutics (MLTX) recorded quarterly Income from Non-Controlling Interests of -$591000.0 in Q4 2025, up 39.01% quarter-over-quarter from -$969000.0 in Q3 2025, and up 21.41% on a YoY basis from -$486782.0 in Q4 2024.
MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
MoonLake Immunotherapeutics' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$591000.0 for Q4 2025.
- In Q4 2025, Income from Non-Controlling Interests rose 21.41% year-over-year to -$591000.0; the TTM figure through Mar 2026 stood at -$2.4 million (up 7.0% YoY), while the FY2025 annual figure was -$3.0 million, down 32.76% from the prior year.
- Income from Non-Controlling Interests was -$591000.0 for Q4 2025 at MoonLake Immunotherapeutics, up from -$969000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $588195.0 in Q4 2022 to a low of -$5.3 million in Q2 2022.
- Historically, Income from Non-Controlling Interests has averaged -$1.6 million across 4 years, with a median of -$831000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests sank 270.59% in 2023, then surged 90.6% in 2024.
- A 4-year view of Income from Non-Controlling Interests shows it stood at $588195.0 in 2022, then tumbled by 270.59% to -$1.0 million in 2023, then rose by 25.06% to -$752000.0 in 2024, then advanced by 21.41% to -$591000.0 in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$591000.0 (Q4 2025), -$969000.0 (Q3 2025), and -$831000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -591,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -831,000.00 |
| Mar 31, 2025 | -615,000.00 |
| Dec 31, 2024 | -752,000.00 |
| Sep 30, 2024 | -724,000.00 |
| Jun 30, 2024 | -480,000.00 |
| Mar 31, 2024 | -302,000.00 |
| Dec 31, 2023 | -1.00 Mn |
| Sep 30, 2023 | -2.19 Mn |
| Jun 30, 2023 | -2.30 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Dec 31, 2022 | 588,195.00 |
| Sep 30, 2022 | -4.58 Mn |
| Jun 30, 2022 | -5.30 Mn |